7 papers · ranked by Valyu relevance
Bárbara Costa, Nuno Vale, Vladimir N. Uversky
Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum-containing regimen. As determined by an FDA-approved test this indication was…
Vanshikha Singh, Afsana Sheikh, Mohammed A. S. Abourehab, Prashant Kesharwani
'Prashant Kesharwani'] Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a beacon of hope for cancer patients. Certain immunotherapies, for example, immune checkpoint inhibitor therapy, monoclonal antibody therapy and chimeric antigen T-cell therapy have garnered extensive…
Faisal K. Alkholifi, Rana M. Alsaffar, Udo Jeschke
Immunomodulation checkpoints usually adopted by healthy cells by tumors might cause an imbalance between host surveillance and tumor progression. Several tumors are incredibly resistant to standard treatment. The dynamic and long-lasting tumor regressions caused by antibodies targeting the PD-1/PD-L1 checkpoint have…
Amita Patnaik, Glen J. Weiss, Drew W. Rasco, Lisa Blaydorn + 8 more
'Amy Mirabella' 'Murali Beeram' 'Wei Guo' 'Sharon Lu' 'Hadi Danaee' 'Kristen McEachern' 'Ellie Im' 'Jasgit C. Sachdev'] Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the…
Annika Auranen, Matthew A. Powell, Vladyslav Sukhin, Lisa M. Landrum + 25 more
TE irAEs occurred in 58.5% of patients in the dostarlimab arm and in 37.0% of patients in the placebo arm ([table1-17588359241277656]). The most common TE irAEs (occurring in ⩾5% of patients in either treatment arm) were arthralgia, infusion-related reactions, hypothyroidism, rash, maculopapular rash, alanine…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Nikolaos Biris, Chunxia Zhao, Julie Macoin, James R. Fuller + 3 more
Atopic dermatitis (AD) is a chronic inflammatory disease sustained by dysregulated T cell activity. The OX40/OX40L pathway drives effector and memory T cell proliferation, survival, and cytokine production, making it a key therapeutic target. STAR-0310, a novel anti-OX40 antibody, binds a noncanonical epitope that…